Champion Oncology (CSBR), AI-Driven Precision Oncology Enhancement… Quarterly sales of $16.6 million 'set a record'

Champions Oncology (CSBR) is strengthening its data-driven “precision oncology” strategy through board restructuring and ongoing performance improvements. The company plans to enhance the efficiency of new drug development by upgrading and integrating patient-derived tumor models with a platform for clinical and molecular data.

On the 30th, local time, Champions Oncology announced the appointment of Brian Alexander, MD, an oncology and data science expert, as a member of the company’s board of directors. Through this appointment, the company aims to further strengthen its “data-driven translational research” capabilities by integrating PDX (patient-derived xenograft tumor) models, multi-omics data, and clinical data. The company is focusing on combining artificial intelligence (AI) with advanced analytics techniques to deepen understanding of diseases and accelerate the discovery of new drug candidates.

In terms of performance, the growth momentum continues. In the third quarter of fiscal year 2026, Champions Oncology achieved revenue of $16.6 million (approximately 239 billion won), setting a record high for research services revenue. Excluding existing data licensing agreements ($4.5 million), this figure increased by 32% year-over-year. Adjusted EBITDA was $0.574 million, with an operating loss of approximately $0.276 million, significantly narrowing the loss. Cash holdings were about $7.1 million, with no debt.

However, as investments expand, costs have also increased. Operating expenses in the same period rose 34.3% year-over-year, mainly due to outsourcing laboratory services, building data platforms, and expanding the sales team. The company expects that internalizing radiolabeling processes will improve profitability.

Earlier, the second-quarter performance also showed a similar trend. For the quarter ending October 2025, service revenue reached $15.0 million (about 216 billion won), up 11.5% year-over-year; profit from oncology services was $7.8 million (about 112 billion won), with profit margins rising to 52%. Adjusted EBITDA was $0.843 million, and net profit was $0.237 million. The company previously set a goal of achieving “profitable growth” based on annual benchmarks while expanding data services and selectively recruiting talent.

Meanwhile, the first quarter experienced a temporary slowdown in profitability. Revenue for the first quarter of fiscal year 2026 was $14.0 million (about 202 billion won), flat compared to the same period last year, but due to declines in service revenue and increased costs, it recorded an operating loss of $0.527 million. Gross margin also decreased to 43%. Nonetheless, with expanded data licensing revenue, the company maintained cash of $10.3 million, keeping its financial position solid.

From an annual perspective, growth is significant. In fiscal year 2025, revenue reached $57.0 million (approximately 820 billion won), up 14% year-over-year, with net profit of $4.6 million and adjusted EBITDA of $7.1 million, successfully improving its profitability structure. Notably, the data business has grown to $4.7 million and is regarded as a “high-yield business.”

Industry observers note that Champions Oncology is evolving into a “hybrid platform company” that integrates data and biological experiments. A biotech investment expert commented: “The architecture connecting PDX models with real patient data is core infrastructure that can increase the success rate of new drug development. When combined with AI analytics, even mid- and small-sized biotech firms can gain differentiated competitive advantages.”

Comment: Although Champions Oncology faces ongoing short-term cost burdens, its strengthening of the “platform first” strategy in the data-driven oncology market highlights its long-term growth potential.